ValueQ3, 24Q4, 24Q1, 25Q2, 25Q3, 25TTMSelling/general/admin expenses12.99 M12.59 M13.91 M11.9 M14.52 M52.91 MResearch & development29.54 M43.42 M58.57 M55.5 M47.75 M205.25 MOperating income32.75 M45.24 M48.84 M62.23 M62.02 M218.33 MNon-Operating Income, Total3.39 M3.93 M3.64 M2.89 M2.29 M12.76 MInterest expense, net of interest capitalized——————Non-Operating Income, excl. Interest Expenses0-14 K000-14 KUnusual income/expense3.39 M3.94 M3.64 M2.89 M2.29 M12.77 MPretax income36.13 M130.98 M52.48 M59.33 M59.73 M302.52 MEquity in earnings——————Taxes—39 M—93 K0—Non-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations29.36 M41.4 M45.2 M59.43 M59.73 M205.75 MDiscontinued operations——————Net income29.36 M41.4 M45.2 M59.43 M59.73 M205.75 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders29.36 M41.4 M45.2 M59.43 M59.73 M205.75 MBasic earnings per share (Basic EPS)-0.54-0.65-0.65-0.85-0.85-3Diluted earnings per share (Diluted EPS)-0.54-0.65-0.65-0.85-0.85-3Average basic shares outstanding54.45 M56.3 M69.77 M69.93 M70.17 M266.16 MDiluted shares outstanding54.45 M56.3 M69.77 M69.93 M70.17 M266.16 MEBITDA——————EBIT-3.59 M—————Cost of revenue736 K—————Other cost of goods sold——————Depreciation & amortization (cash flow)—427 K497 K538 K576 K2.04 M
EyePoint Inc
EyePoint Pharmaceuticals Inc. is a Watertown, Massachusetts company specialising in the application of microelectromechanical systems and nanotechnology to drug delivery.
pSivida obtained porous silicon technology from the British government Defence Evaluation and Research Agency. QinetiQ continues to be a strategic partner.
In June 2004, pSivida acquired full ownership of pSiMedica. In April 2018, pSivida purchased eye products firm Icon Bioscience. Afterwards, it rebranded to its current name of EyepOint Pharmaceuticals, Inc.